The Effect of Intrawound Vancomycin Powder in Spine Surgery

Sponsor
Windsor-Essex Compassionate Care Community (Other)
Overall Status
Recruiting
CT.gov ID
NCT04825522
Collaborator
Cairo University (Other)
1,643
2
2
20.2
821.5
40.7

Study Details

Study Description

Brief Summary

Problem: Postoperative wound infection following various spinal surgeries is a serious complication. The incidence of post-surgical wounds in spine surgery is high, and various researchers have reported different infection rates. In addition, increased healthcare costs, prolonged lengths of stay in hospital, and reduced quality of life as a result of surgical site infections (SSI) are also major concerns. Several methods for avoiding SSI, such as betadine irrigation, vacuum-assisted closure, and intra-wound vancomycin powder, have been used to reduce the rate of wound infection in spine surgery. Use of local vancomycin has been popular because of its protective effects and lower cost. According to some reports, prophylactic administration of intra-wound vancomycin powder before wound closure is an effective method for decreasing postoperative wound infection rates; however, other studies have revealed a non-significant effect of intra-wound vancomycin use for decreasing the postsurgical wound infection rate.

Solution: Therefore, the investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Potential participants will be identified at the clinic, emergency department, or on the floor by history, clinical examination, and positive imaging findings. The surgeon will notify the study coordinator of the potential patient. The study coordinator will introduce the trial to the patient and obtain informed consent at the office during the clinic visit or his hospital stay. Patient's pre-operative data such as demographics (age and sex), presence of comorbidities like diabetes, ischemic heart disease, asthma patients on steroids, nutrition status using serum albumin level, and previous posterior spine surgical procedures at the operative level will be collected once the patient admitted prior to the procedure. The study coordinator will enroll the patient into the trial, and provide the appropriate intervention (vancomycin application, or no application) using the closed envelope technique of randomization to the neurosurgeon performing the procedure. Patients will also be blinded to avoid the placebo effect. All patients will receive the standard systemic antibiotic prophylaxis. The duration of the procedure, estimated blood loss, type of the procedure (instrumented versus non-instrumented) and the number of levels will be recorded. After the intervention, wound infections will be monitored during a follow-up period of 12 weeks from the date of surgery. Cultured organisms and subsequent treatments will be recorded. The primary outcome is the incidence of infection (either in-patient or in the follow-up). The secondary outcome is the development of other complications including Vancomycin related.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1643 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Experimental Group: For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied. Control Group: Will not receive any extra treatment.Experimental Group: For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied. Control Group: Will not receive any extra treatment.
Masking:
Single (Participant)
Masking Description:
The patients will not know if they received vancomycin or not.
Primary Purpose:
Prevention
Official Title:
The Effect of Intrawound Vancomycin Powder in Spine Surgery: A Prospective Randomized Controlled Trial
Actual Study Start Date :
Mar 27, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Participants will not be receiving vancomycin.

Active Comparator: Vancomycin

For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.

Drug: Vancomycin
During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
Other Names:
  • Treatment group
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of Infection [3 months]

      Number of patients with post-operative wound infection after spinal surgery (including the type of organism and duration of the procedure). Investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.

    Secondary Outcome Measures

    1. Complications [3 months]

      Number of patients who developed any complications related to the vancomycin.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients requiring surgery due to any spine disease.
    Exclusion Criteria:
    • A previous history of infections at the spine surgical site.

    • Biopsy procedure.

    • Patients with a postoperative follow-up time of less than 12 weeks.

    • Patients allergic to vancomycin.

    • Patient is less than 18 years old.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Windsor Regional Hospital - Ouellette Windsor Ontario Canada N9A 1E1
    2 Cairo University Hospitals Cairo Egypt 11562

    Sponsors and Collaborators

    • Windsor-Essex Compassionate Care Community
    • Cairo University

    Investigators

    • Principal Investigator: Mohamed Soliman, MD, Western University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Mohamed Soliman, Assistant Professor of Neurosurgery, General Neurosurgery Clinical Fellow, Principle Investigator, Windsor-Essex Compassionate Care Community
    ClinicalTrials.gov Identifier:
    NCT04825522
    Other Study ID Numbers:
    • REB# 21-393
    First Posted:
    Apr 1, 2021
    Last Update Posted:
    Apr 27, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 27, 2022